Seelos Therapeutics Share Holder Equity 2010-2022 | SEEL

Seelos Therapeutics share holder equity from 2010 to 2022. Share holder equity can be defined as the sum of preferred and common equity items
Seelos Therapeutics Annual Share Holder Equity
(Millions of US $)
2021 $57
2020 $3
2019 $-0
2018 $-5
2017 $4
2016 $-8
2015 $-10
2014 $2
2013 $11
2012 $7
2011 $5
2010 $12
2009 $3
Seelos Therapeutics Quarterly Share Holder Equity
(Millions of US $)
2022-03-31 $46
2021-12-31 $57
2021-09-30 $73
2021-06-30 $83
2021-03-31 $25
2020-12-31 $3
2020-09-30 $7
2020-06-30 $4
2020-03-31 $7
2019-12-31 $-0
2019-09-30 $10
2019-06-30 $5
2019-03-31 $3
2018-12-31 $-5
2018-09-30 $4
2018-06-30 $5
2018-03-31 $4
2017-12-31 $4
2017-09-30 $6
2017-06-30 $7
2017-03-31 $1
2016-12-31 $-8
2016-09-30 $-8
2016-06-30 $-9
2016-03-31 $-7
2015-12-31 $-10
2015-09-30 $-8
2015-06-30 $-3
2015-03-31 $2
2014-12-31 $2
2014-09-30 $12
2014-06-30 $12
2014-03-31 $9
2013-12-31 $11
2013-09-30 $12
2013-06-30 $13
2013-03-31 $-1
2012-12-31 $7
2012-09-30 $24
2012-06-30 $17
2012-03-31 $20
2011-12-31 $5
2011-09-30 $6
2011-06-30 $6
2011-03-31 $12
2010-12-31 $12
2010-09-30
2010-06-30 $17
2010-03-31 $5
2009-12-31 $3
2009-09-30 $2
2009-06-30 $2
2009-03-31 $3
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.065B $0.000B
Seelos Therapeutics Inc. is a clinical-stage biopharmaceutical company. It focused on the development and advancement of novel therapeutics to address unmet medical needs for central nervous system disorders. The company's product pipeline consists of SLS-002, SLS-006, SLS-008, SLS-010 and SLS-012 which are in clinical stage. Seelos Therapeutics Inc., formerly known as Apricus Biosciences Inc., is based in New York, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $162.107B 9.86
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.761B 16.99
Biohaven Pharmaceutical Holding (BHVN) United States $10.111B 0.00
Ginkgo Bioworks Holdings (DNA) United States $5.648B 0.00
Emergent Biosolutions (EBS) United States $1.770B 7.57
Arcus Biosciences (RCUS) United States $1.376B 34.89
Myovant Sciences (MYOV) United Kingdom $1.033B 0.00
Zymeworks (ZYME) Canada $0.397B 0.00
Gelesis Holdings (GLS) United States $0.345B 0.00
Ambrx Biopharma (AMAM) United States $0.157B 0.00
Enzo Biochem (ENZ) United States $0.110B 22.60
SQZ Biotechnologies (SQZ) United States $0.100B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00